Mr. Dennis Wilson reports

CONVALO HEALTH INTERNATIONAL, CORP. ANNOUNCES INCREASE OF PREVIOUSLY ANNOUNCED BOUGHT DEAL FINANCING TO $15 MILLION

Convalo Health International Corp., in connection with its previously announced bought-deal private placement offering, has entered into an amendment agreement with Mackie Research Capital Corp., as lead underwriter, and Beacon Securities Ltd. to upsize the offering from $7.5-million to $15-million. The underwriters have agreed to purchase, on a bought-deal basis, 37.5 million units of the company at a price of 40 cents per unit, for gross proceeds to the company of $15-million.

Each unit will consist of one common share in the capital of Convalo and one warrant of Convalo. Each warrant entitles the holder thereof to acquire one common share for an exercise price of 50 cents per common share for a period of 36 months following closing of the offering. The expiry date of the warrants may be accelerated by Convalo at any time following the six-month anniversary of the closing, and prior to the expiry date of the warrants, if the volume-weighted average trading price of the common shares is greater than 60 cents for any 20 consecutive trading days.

The company has granted the underwriters an option to increase the size of the offering by up to an additional 15 per cent of the total number of units to be issued under the offering, at any time on or before 48 hours prior to the closing.

The offering is scheduled to close on or about the week of April 20, 2015, and is subject to certain conditions, including but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The securities to be issued under the offering will have a hold period of four months and one day from the closing. The net proceeds from the offering will be used by Convalo for acquisition purposes and general working capital.

We seek Safe Harbor.